Jerry Yan

This study shows that sustained delivery of a SARS-CoV-2 subunit vaccine in an adjuvanted hydrogel depot improves antibody responses in nonhuman primates compared to bolus vaccination.

This study develops a hydrogel-based vaccine delivery system that enhances immune responses and reduces reactogenicity in aged mice compared to Shingrix.

This paper develops a hydrogel depot system for long-acting peptide delivery, showing sustained release and improved therapeutic outcomes in rodents.

This paper develops long-acting hydrogel-based depot formulations of semaglutide and tirzepatide that maintain drug levels for over 6 weeks in a rat model, showing similar efficacy to daily injections.

This paper develops ACTIVATE, a hydrogel-based platform that enhances tumor control by synergizing adoptive and endogenous immunity through localized cytokine delivery and T-cell activation.

This paper develops a hydrogel depot system to prolong the release of broadly neutralizing antibodies, showing improved pharmacokinetics and reduced immune cell-mediated release through co-formulation with anti-inflammatory agents.

This study shows sustained delivery of multivalent influenza vaccines via polymer-nanoparticle hydrogels enhances rapid, consistent, and broad humoral immunity against homologous and heterologous strains.

This paper develops a multivalent liposomal hydrogel vaccine that generates broad and durable anti-coronavirus antibody responses in mice.

This paper develops a modular saponin-based nanoparticle adjuvant platform incorporating TLR agonists, showing improved vaccine potency and breadth against COVID-19 and HIV in mice.